Last reviewed · How we verify
Darolutamide plus ADT treatment
Darolutamide plus ADT treatment is a Small molecule drug developed by Bayer. It is currently in Phase 2 development.
At a glance
| Generic name | Darolutamide plus ADT treatment |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer (PHASE2)
- Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
- A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer
- Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer (PHASE2)
- A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) (PHASE4)
- PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
- Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer (PHASE2)
- A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Darolutamide plus ADT treatment CI brief — competitive landscape report
- Darolutamide plus ADT treatment updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about Darolutamide plus ADT treatment
What is Darolutamide plus ADT treatment?
Darolutamide plus ADT treatment is a Small molecule drug developed by Bayer.
Who makes Darolutamide plus ADT treatment?
Darolutamide plus ADT treatment is developed by Bayer (see full Bayer pipeline at /company/bayer).
What development phase is Darolutamide plus ADT treatment in?
Darolutamide plus ADT treatment is in Phase 2.
Related
- Manufacturer: Bayer — full pipeline
- Compare: Darolutamide plus ADT treatment vs similar drugs
- Pricing: Darolutamide plus ADT treatment cost, discount & access